Skip to main content

Table 1 Disease indications with greater than 5% of specimens showing high TMB (>20 mutations/Mb)

From: Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Disease type

Specimen count

Median mutations/Mb

Percentage cases with >20 mutations/Mb (95% CI)

Skin basal cell carcinoma

92

47.3

70.7 (60.7–79)

Skin squamous cell carcinoma (SCC)

266

45.2

67.3 (61.4–72.7)

Skin melanoma

879

14.4

39.7 (36.4–42.9)

Skin merkel cell carcinoma

206

4.3

37.9 (31.5–44.7)

Unknown primary melanoma

1324

12.6

37.6 (35–40.2)

Head and neck melanoma

59

6.3

25.4 (14.7–36)

Lung large cell carcinoma

74

12.2

24.3 (14.9–33.7)

Unknown primary squamous cell carcinoma (SCC)

606

7.6

21.6 (18.4–24.9)

Lung large cell neuroendocrine carcinoma

288

9.9

19.8 (15.6–24.8)

Lung sarcomatoid carcinoma

130

7.2

19.2 (12.7–26)

Stomach adenocarcinoma intestinal type

58

5.0

19 (10.9–30.9)

Uterus endometrial adenocarcinoma endometrioid

459

4.5

18.5 (15–22.1)

Lymph node lymphoma diffuse large B cell

348

10.0

18.4 (14.7–22.8)

Lung non-small cell lung carcinoma (NOS)

2636

8.1

17 (15.6–18.5)

Unknown primary sarcomatoid carcinoma

64

5.4

15.6 (7.6–24.6)

Unknown primary malignant neoplasm (NOS)

491

3.8

14.9 (12–18.3)

Uterus endometrial adenocarcinoma (NOS)

743

4.5

14.7 (12.3–17.4)

Bladder carcinoma (NOS)

77

8.1

14.3 (8.2–23.8)

Unknown primary urothelial carcinoma

188

7.2

13.8 (9.2–18.9)

Soft tissue angiosarcoma

157

3.3

13.4 (8.9–19.6)

Lung adenocarcinoma

11855

6.3

12.3 (11.7–12.9)

Lung adenosquamous carcinoma

154

5.4

12.3 (7.5–17.7)

Skin adnexal carcinoma

74

3.6

12.2 (6.5–21.5)

Bladder urothelial (transitional cell) carcinoma

1218

7.2

11.9 (10.1–13.8)

Lymph node lymphoma B-cell (NOS)

88

6.3

11.4 (6.3–19.7)

Lung squamous cell carcinoma (SCC)

2102

9.0

11.3 (10–12.7)

Unknown primary carcinoma (NOS)

1405

4.5

10.7 (9.2–12.4)

Head and neck squamous cell carcinoma (HNSCC)

1184

5.0

10.1 (8.5–11.9)

Lung small cell undifferentiated carcinoma

913

9.9

9 (7.3–11)

Nasopharynx and paranasal sinuses squamous cell Carcinoma (SCC)

67

4.5

9 (4.2–18.2)

Ovary endometrioid adenocarcinoma

105

3.6

8.6 (4.6–15.5)

Unknown primary undifferentiated small cell carcinoma

117

6.3

8.5 (4.1–14)

Brain oligodendroglioma

321

2.7

8.4 (5.6–11.6)

Small intestine adenocarcinoma

277

4.5

8.3 (5.3–11.7)

Soft tissue malignant peripheral nerve sheath tumor (MPNST)

134

2.5

8.2 (4.1–13.2)

Soft tissue sarcoma undifferentiated

260

2.5

8.1 (5.3–12)

Uterus endometrial adenocarcinoma clear cell

62

3.6

8.1 (3.5–17.5)

Prostate undifferentiated carcinoma

91

3.6

7.7 (3.8–15)

Salivary gland mucoepidermoid carcinoma

55

2.7

7.3 (2.9–17.3)

Unknown primary adenocarcinoma

2751

3.6

6.9 (6–7.9)

Ureter urothelial carcinoma

88

5.4

6.8 (2.5–12.6)

Cervix squamous cell carcinoma (SCC)

284

5.4

6.7 (4.3–10.2)

Penis squamous cell carcinoma (SCC)

60

4.5

6.7 (2.6–15.9)

salivary gland carcinoma (NOS)

160

3.6

6.3 (3.4–11.1)

Kidney urothelial carcinoma

224

5.4

6.3 (3.8–10.2)

Unknown primary undifferentiated neuroendocrine carcinoma

674

2.7

6.1 (4.5–8.1)

Duodenum adenocarcinoma

249

3.6

6 (3.4–9.2)

  1. CI confidence interval, NOS not otherwise specified